A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body. These cells, ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

Fresenius and Charles River Laboratories are among 18 academic, research, industry and clinical partners that have formed a new European Union-supported consortium to develop an automated, ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with CURE that the Food and Drug Administration (FDA) removal of primary central ...

H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...

A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body.